Malignant neoplasm of stomach
|
0.380 |
PosttranslationalModification
|
disease |
BEFREE |
In this study, we assessed the relationship between TIMP-3 promoter methylation and gastric cancer risk by performance of a meta-analysis.
|
27314831 |
2016 |
Malignant neoplasm of stomach
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
The Aζ values of the receiver operator characteristic curve for methylated TIMP-3 were 0.966 and 0.922 for serum and preoperative peritoneal washes, respectively, compared with those in GC tissues.
|
25357107 |
2014 |
Malignant neoplasm of stomach
|
0.380 |
Biomarker
|
disease |
BEFREE |
We consider that MMP2, MMP24, and MMP25 and the proteins MMP-14 and TIMP-3 could be candidates for prognostic molecular markers in GC.
|
24669030 |
2014 |
Malignant neoplasm of stomach
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
The hypermethylation of the promoter region in CpG islands is the main mechanism of TIMP3 gene expression and may provide evidence for the molecular diagnosis and stage evaluation of gastric cancer.
|
23819566 |
2013 |
Malignant neoplasm of stomach
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
We also analyzed TIMP-3 protein expression by immunohistochemistry and its association with clinicopathological characteristics in two cohorts of gastric cancer comprising a total of 347 patients.
|
18516293 |
2008 |
Malignant neoplasm of stomach
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Eight genes (BRCA1, p73, RARbeta, hMLH1, RIZI, RUNX3, MGMT, and TIMP3) were statistically associated with a particular variant of gastric cancer, the signet-ring cell type (P = 0.03).
|
18829507 |
2008 |
Malignant neoplasm of stomach
|
0.380 |
Biomarker
|
disease |
CTD_human |
Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.
|
16367923 |
2006 |
Malignant neoplasm of stomach
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Five different classes of methylation behaviors were found: (1) genes methylated in GC only (GSTP1 and RASSF1A); (2) genes showing low methylation frequency (<12%) in CG, IM, and GA, but significantly higher methylation frequency in GC (COX-2, hMLH1, and p16); (3) a gene with low and similar methylation frequency (8.8-21.3%) in four-step lesions (MGMT); (4) genes with high and similar methylation frequency (53-85%) in four-step lesions (APC and E-cadherin); and (5) genes showing an increasing tendency with or without fluctuation of the methylation frequency along the progression (DAP-kinase, p14, THBS1, and TIMP3).
|
12746473 |
2003 |
Malignant neoplasm of stomach
|
0.380 |
Biomarker
|
disease |
BEFREE |
Five different classes of methylation behaviors were found: (a). genes methylated in GC only (GSTP1 and RASSF1A), (b). genes showing low methylation frequency (<12%) in CG, IM, and gastric adenoma (GA) but significantly higher methylation frequency in GC (COX-2, hMLH1, p16), (c). a gene with low and similar methylation frequency (8.8-21.3%) in four-step lesions (MGMT), (d). genes with high and similar methylation frequency (53-85%) in four-step lesions (APC and E-cadherin), and (e). genes showing an increasing tendency with or without fluctuation of the methylation frequency along the progression (DAP-kinase, p14, THBS1, and TIMP-3).
|
12695555 |
2003 |